With such debilitating symptoms, the need for research and patient support for inflammatory bowel conditions is crucial.
The Hospital Research Foundation Group is proud to partner with BiomeBank, which is a world-leader in treating and preventing diseases by replenishing gut microbial ecology.
Inflammatory Bowel Disease Support
Supporting health biotech company BiomeBank in facilitating safe faecal microbiota transplantation (FMT) for people suffering from clostridium difficile (C-diff) infection and ulcerative colitis, replenishing their healthy gut bacteria and substantially improving their symptoms and quality of life.
BiomeBank’s quality-controlled screening, storage, processing and transport practices makes it a world-leader in FMT.
Using both diet strategies and faecal microbiota transplantation (FMT) to improve the diversity and quality of a patient’s gut microbiome, which is often lacking in IBD patients.
Researcher
Associate Professor Robert Bryant has been awarded a prestigious Michell-McGrath Fellowship to advance treatments for people with IBD.
Investigating diet strategies to help reduce harmful gut bacteria and reduce inflammation in ulcerative colitis.
Researcher
Dr Robert Bryant (left) wants to find a new treatment for this debilitating disease, which causes long-lasting inflammation and ulcers in your digestive tract.
Running a clinical trial to investigate whether faecal microbiota transplantation (FMT) can help improve the gut health of people living with Parkinson’s and ease symptoms such as constipation.
Who it benefits
Cassandra Hewett lives with Young Onset Parkinson’s and hopes this research can change her life!
Implementing a new software program at the Royal Adelaide Hospital to support the day-to-day management of patients’ inflammatory bowel conditions.
Researcher
Professor Jane Andrews hopes to roll out the program to The Queen Elizabeth, Flinders and Lyell McEwin sites next.
